Pregnancy outcomes in alemtuzumab treated women with multiple sclerosis: a case series

Data on pregnancy outcome in alemtuzumab-treated women are scarce and derived from safety reports of clinical trials. We report on seven women with overall eight pregnancies during treatment with alemtuzumab in a real-world setting. All pregnancies occurred within 9 months after alemtuzumab treatmen...

Full description

Saved in:
Bibliographic Details
Published inNeurological sciences Vol. 42; no. 8; pp. 3427 - 3430
Main Authors Valeria, Russo Cinzia, Roberta, Lanzillo, Francesco, Saccà, Marcello, Moccia, Antonio, Carotenuto, Vincenzo, Brescia Morra
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 01.08.2021
Springer Nature B.V
Subjects
Brief Communication
Clinical trials
Congenital defects
Cytomegalovirus
Medicine
Medicine & Public Health
Monoclonal antibodies
Multiple sclerosis
Neurology
Neuroradiology
Neurosciences
Neurosurgery
Pregnancy
Psychiatry
Pregnancy
Cytomegalovirus
Multiple sclerosis
Alemtuzumab
Disease modifying treatment
Breastfeeding
Online AccessGet full text

Cover

More Information
Summary:Data on pregnancy outcome in alemtuzumab-treated women are scarce and derived from safety reports of clinical trials. We report on seven women with overall eight pregnancies during treatment with alemtuzumab in a real-world setting. All pregnancies occurred within 9 months after alemtuzumab treatment, and two of them within 4 months despite patients being informed on pregnancy prevention. We found one congenital cytomegalovirus infection, one spontaneous abortion, one elective abortion due to extrauterine pregnancy, and five live births without congenital abnormalities or birth defects.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1590-1874
1590-3478
DOI:10.1007/s10072-020-04975-5